Evidence map›Paper›PMID 36785595›Full record

ArticleThe Egyptian journal of internal medicine2023

A case of reinfection with a different variant of SARS-CoV-2: case report.

Nagashige Shimada, Masahiro Shinoda, Hiroaki Takei, Yuto Yoshida, Masashi Nishimura, Mio Kousaka, Miwa Morikawa, Takashi Sato, Hiroto Matsuse, Masaharu Shinkai

Open access · diamondAbstract readCase Reports
In one paragraph

Article in The Egyptian journal of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Nagashige ShimadaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Masahiro ShinodaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.ORCID 0000-0002-0288-5637
Hiroaki TakeiDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Yuto YoshidaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Masashi NishimuraDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Mio KousakaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Miwa MorikawaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Takashi SatoDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Hiroto MatsuseDivision of Respiratory Medicine, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Masaharu ShinkaiDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
New Tokyo Hospital · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronavirus disease 2019 (COVID-19) was previously thought to have a low reinfection rate, but there are concerns that the reinfection rate will increase with the emergence and spread of mutant variants. This report describes the case of a 36-year-old, non-immunosuppressed man who was infected twice by two different variants of COVID-19 within a relatively short period. Case presentation: A 36-year-old Japanese man with no comorbidities was infected with the E484K variant (R.1 lineage) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms were mild and improved with symptomatic treatment alone. About four months later he presented to another outpatient department with high fever and headache. We diagnosed him as infected with the Alpha variant (B.1.1.7) of SARS-CoV-2 based on SARS-CoV-2 real-time reverse transcription polymerase chain reaction testing (RT-PCR). The patient was hospitalized with high fever. The patient received treatment in the form of anti-inflammatory therapy with corticosteroid and antibacterial chemotherapy. The patient improved without developing severe disease. Conclusion: Concerns have been raised that the reinfection rate of COVID-19 will increase with the emergence of mutant variants. Particularly in mild cases, adequate amounts of neutralizing antibodies may not be produced, and reinfection may thus occur. Continued attention to sufficient infection control is thus essential.

Indexed as

Alpha variantE484KN501YReinfectionSARS-CoV-2Variant

Identifiers

PMID36785595
PMCPMC9907179
OpenAlexW4319596318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.